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Abstract
The parapharyngeal space is a complex anatomical area. Primary parapharyngeal
tumors are rare tumors and 80% of them are benign. A variety of tumor types can
develop in this location; most common are salivary gland neoplasm and neurogenic
tumors. The management of these tumors has improved greatly owing to the devel-
opments in imaging techniques, surgery, and radiotherapy. Most tumors can be
removed with a low rate of complications and recurrence. The transcervical
approach is the most frequently used. In some cases, minimally invasive
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approaches may be used alone or in combination with a limited transcervical route,
allowing large tumors to be removed by reducing morbidity of expanded
approaches. An adequate knowledge of the anatomy and a careful surgical plan is
essential to tailor management according to the patient and the tumor. The purpose
of the present review was to update current aspects of knowledge related to this
more challenging area of tumor occurrence.
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1 | INTRODUCTION
Parapharyngeal space (PPS) tumors form a heterogeneous
group of lesions arising in an anatomically complex region,
which is challenging to examine clinically due to its deep
neck location lateral to the pharynx and medial to the jaw.
These lesions are uncommon accounting for approximately
0.5% of all head and neck tumors.1 Salivary gland tumors
are the most common, followed by neurogenic neoplasms.2
Most lesions in this region are benign (80%), and surgical
excision is the standard primary treatment.2–4 To provide
adequate preoperative counseling and to reduce patient mor-
bidity, the surgeon must have a thorough understanding of
treatment of these tumors.
The diagnostics and management of PPS tumors form a
challenge because of their low occurrence rate, anatomical
relationships, and histological diversity. The relevant litera-
ture on PPS tumors is growing but is still limited to rather
small case series. Several systematic reviews have recently
been published, focusing on the frequency of the various his-
tological subtypes and surgical approaches used.2,3,5 This
article reviews the anatomy, pathology, clinical and radio-
logic evaluation, and surgical treatment of primary PPS
tumors, highlighting new surgical approaches and nonsurgi-
cal treatment.
2 | ANATOMY
PPS is located in the suprahyoid neck with a shape resem-
bling an inverted pyramid with the floor at the skull base
and its tip at the greater horn of the hyoid bone.6 The supe-
rior limit of the PPS is a small portion of the petrous portion
of the temporal bone and the sphenoid bone. It includes the
carotid canal, the jugular foramen, and the hypoglossal fora-
men. Laterally, there is a fascial connection from the medial
pterygoid plate to the spine of the sphenoid, which crosses
medial to the foramen ovale and foramen spinosum, which
are not included in this space but are rather located in the
infratemporal fossa.7 The inferior boundary is the junction
of the posterior belly of the digastric muscle and the greater
cornu of the hyoid bone. The PPS is blended into the poste-
rior aspect of submandibular space on this level. Medially,
the boundary consists of the buccopharyngeal or visceral fas-
cia overlying the pharyngobasilar fascia and pharyngeal con-
strictors muscles. The lateral boundary includes the fascia
over the medial pterygoid muscle, the ramus of the mandi-
ble, the posterior belly of the digastric muscle, and the fascia
over the retromandibular deep portion of the parotid gland.
Anteriorly, the limit is the pterygomandibular raphe. The
posterior limit is the dorsal layer of fascia making up the
carotid sheath. The internal carotid artery (ICA), internal
jugular vein (IJV), cranial nerves IX-XII, and sympathetic
chain all course through this space.
A key anatomical division of the PPS is into prestyloid
and retrostyloid compartments, facilitating differential diag-
nosis of PPS lesions. Fascia runs posteriorly from the styloid
process to the tensor veli palatini muscle, called the tensor-
vascular-styloid fascia, because it also contains the ascend-
ing palatine artery and vein, divides the PPS into an antero-
lateral or prestyloid and a posteromedial, or retrostyloid
compartments. Assessment can be made on imaging based
upon displacement of the PPS fat, with posteriorly based
tumors displacing fat anteriorly and anterior tumors displa-
cing fat posteriorly.8 The prestyloid compartment contains
fat, a portion of the retromandibular parotid gland, and some
lymph nodes. The retrostyloid compartment contains the
ICA, IJV, lower cranial nerves (IX-XII), sympathetic chain,
and lymph nodes. PPS tumors may arise from each of these
structures, which are at risk during surgery. The PPS con-
tains numerous lymphatics, which along with the retrophar-
yngeal nodes drain the soft palate, paranasal sinuses,
posterior oral cavity, base of tongue, and a portion of the
thyroid gland. The parapharyngeal nodes superiorly are con-
nected to the node of Rouvière in the lateral most retrophar-
yngeal space; this can be a site of metastasis from the
nasopharynx, upper oropharynx, and paranasal sinuses.
The stylomandibular tunnel is bounded by the posterior
ramus of the mandible, the skull base, and the stylomandibu-
lar ligament. Deep lobe parotid tumors can extend into the
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prestyloid PPS posterior to the stylomandibular ligament
resulting in a “dumbbell”-shaped mass.6
Prasad et al9 have proposed that the PPS could be
divided into three alternative compartments with diagnostic
and surgical implications: the upper, the middle, and lower
part. The inferior border of the lateral pterygoid muscle
divides the upper and middle portions, while an imaginary
line joining the angles of the jaw on both sides separates the
middle from the lower. This compartmentalization parallels
the best surgical approach for each tumor.
3 | PATHOLOGY
According to a systematic review by Riffat et al,2 tumors
from up to 70 histological subtypes can be identified in the
PPS (Table 1). Approximately 80% of these tumors are
benign and 20% malignant.2,5 Prestyloid tumors are more
common (59%) than retrostyloid ones (26%); although, in
some cases, it is difficult to determine the exact origin of the
tumor (prestyloid/retrostyloid) (15%).14 PPS tumors can be
grouped into three categories: primary, extension from adja-
cent structures, and metastatic.
Primary PPS neoplasms, the subject of this review, fall
into three main categories: salivary gland neoplasms (presty-
loid) (45%), neurogenic tumors (retrostyloid) (45%), and
miscellaneous tumors (10%).2 Moreover, direct extension of
tumors into the PPS can occur from the mandible, maxilla,
nasopharynx, neck, oral cavity, oropharynx, and temporal
bone. It is important to note that some series of PPS tumors
include all deep lobe parotid tumors, lesions originating at
the foramen ovale, and carotid body paragangliomas. These
cases should be excluded and only tumors that affect at least
the retromandibular part of the deep lobe of the parotid and
carotid body paragangliomas localized above the posterior
belly of the digastric should be considered PPS tumors.
Lesions arising at the foramen ovale should be considered as
infratemporal fossa tumors. Metastatic tumors to Rouvières
nodes (less than 5%) include thyroid gland carcinomas,
squamous cell carcinomas, including nasopharyngeal type,
esthesioneuroblastomas, sarcomas, and other unspecified
lesions.
4 | SALIVARY GLAND TUMORS
Salivary gland tumors are the most common PPS tumors
accounting for 40%-50% of cases,2,15,16 although in some
series, neurogenic tumors are reported more frequently.10
These tumors are located in the prestyloid space and can
arise from either the deep lobe of the parotid gland (less than
5% of parotid tumors involve the PPS) or from minor sali-
vary glands. A fat plane on CT or MRI between the mass
and the parotid helps distinguish a tumor of minor salivary
origin from a deep lobe parotid tumor. Unfortunately, in
clinical practice, it is not always clear if this fat plane is
intact over the whole surface between parotid gland and
tumor, making discrimination between parotid and minor
salivary gland tumors difficult.
More than 15 different histological types of salivary
gland tumors have been reported in the PPS.2 The vast
majority (80%) of these salivary lesions are benign. Pleo-
morphic adenoma is the commonest PPS tumor (up to 30%
TABLE 1 Histopathological diagnosis of the most frequent PPS tumorsa
Pathology Frequency
Salivary tumors 45%
• Benign 80%
• Pleomorphic adenoma 50%
• Other benignb 30%
• Malignant 20%
• Adenoid cystic carcinoma 9%
• Mucoepidermoid carcinoma 5%
• Carcinoma ex-pleomorphic adenoma 1%
• Squamous cell carcinoma 1%
• Adenocarcinoma 1%
• Myoepithelial carcioma 1%
• Neurogenic lesions 1%
• Other malignantc 1%
Neurogenic tumors 45%
• Benign 95%
• Vagal paraganglioma 35%
• Schwannoma 50%
• Neurofibroma 5%
• Sympathetic paraganglioma 1%
• Other benign 4%
• Malignant 5%
• Malignant PNST 1%
• Malignant paraganglioma 1%
• Other unspecified malignant lesions 3%
Miscellaneous 10%
• Benign 70%
• Branchial cleft cyst 10%
• Arteriovenous malformations 1%
• Otherd 59%
• Malignant 30%
• Chondrosarcoma 1%
• Rhabdomyosarcoma 1%
• Undifferentiated carcinoma 1%
• Lymphoid lesions 1%
• Other unspecified malignant lesions 26%
a These global data come from recent studies of patients with PPS
tumors.2,3,5,10–13 Different proportions can be found in some series.
b Other benign salivary tumors include Warthin´s tumor, basal cell adenoma,
myoephitelioma, monomorphic adenoma, lymphoepitelial lesion, granuloma-
tous parotitis, and other unspecified lesions.
c Other malignant salivary tumors include acinic cell carcinoma, undifferentiated
carcinoma, and other unspecified lesions.
d Other benign miscellaneous lesions include meningiomas, cystic higroma,
aneurysm, lymphangioma, leiomyoma, lipoma, osteolipoma, fibromatosis, des-
moid tumor, fibromyxoma, fibrous tumor, cysts, inflammatory pseudotumor,
and other unspecified lesions.
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of PPS lesions and 60% of salivary gland tumors). Malignant
tumors account for a 20% of all salivary gland tumors, with
adenoid cystic (less than 10%) and mucoepidermoid carci-
noma (less than 5%) being the most common ones.2
5 | NEUROGENIC TUMORS
Neurogenic tumors account for 40% of PPS neoplasms and
are grouped into three main histological subtypes: paragan-
gliomas, schwannomas, and neurofibromas.2 The vast
majority of neurogenic tumors (95%) are benign. Depending
on the reported series, either paragangliomas2 or schwanno-
mas17,18 is the most frequent histological subtypes. Although
paragangliomas are not strictly neurogenic tumors as they
arise from paraganglia, in most series, they are included in
this category, because they may intimately be associated
with cranial nerves, such as jugular paragangliomas, which
do not arise in nervous structures but can expand to include
nerves. For this reason, we have included them in this group.
Malignant peripheral nerve sheath tumors (PNSTs) are the
most common malignant neurogenic lesions.2
The most common PPS paragangliomas arise from the
vagus nerve (CN X) (retrostyloid). Multiple paragangliomas
may occur synchronously or metachronously. Multicentric
tumors occur in 10%-20% of all head and neck paraganglio-
mas. However, reports of much higher incidence of multiple
tumors, like 40% for sporadic form and 80% for familial
variety, can be found. Bilateral tumors have been reported in
up to 10% of sporadic cases and 30% of hereditary cases.
These tumors can secrete catecholamines 2% of the time,
causing hypertension and flushing. This is an important peri-
operative consideration, and patients with these symptoms
should have a 24-hour urine collection evaluated for cate-
cholamines, vanillylmandelic acid, and metanephrines.19
Perioperative beta blockade may be indicated in patients
with secreting tumors. The genetics of these hereditary
tumors are related to mutations of the succinate dehydroge-
nase (SDH) genes. Genetic testing of patients with a positive
family history and/or multiple tumors is recommended.
Malignancies have been reported in 6%-19%. The malignant
nature is demonstrated by imaging studies that reveal
regional or distant metastasis. As the presence of lymph
node metastases may be the only sign of malignancy, it is
recommended that lymph nodes be removed during resec-
tions of these tumors, especially in cases of vagal paragan-
gliomas and those carriers of the SDHB mutation, in which
the rate of malignancy is slightly higher. For paragangliomas
that occur in the neck, levels II and III are easily addressed
and samples should be taken. In cases of preoperative lymph
node involvement by paraganglioma, modified neck dis-
section is indicated. It should minimally address levels II to
IV. Histologically, the difference between benign and malig-
nant paragangliomas cannot be made.20
Schwannomas are retrostyloid lesions. The most com-
mon site of origin is the vagus nerve (CN X), while the sym-
pathetic chain is the second. Nevertheless, tumors
originating from cranial nerves IX, XI, and XII have been
also described. They usually do not cause functional impair-
ment of their nerve of origin, but as they enlarge, they can
present as a mass and affect the function of adjacent nerves.
These lesions can extend up through the jugular foramen
intracranially. Less than 1% will undergo malignant transfor-
mation. Treatment requires enucleation and, although post-
operative neurological deficit of the nerve involved is almost
always inevitable, it is sometimes possible to preserve the
nerve involved, particularly when capsule is opened via a
vertical incision minimizing the risk of injury of the nerve
fibers running into the periphery of the tumor and use of
intraoperative nerve monitoring for vagal schwannomas
using an endotracheal tube monitoring device for vocal-fold
motion response.21
Neurofibromas may also occur as retrostyloid lesions.
They originate from the Schwann cells and perineural fibro-
blasts. These tumors are unencapsulated and intimate
involvement of the nerve of origin is common. Sites of ori-
gin include the vagal nerve, glossopharyngeal nerve (IX),
sympathetic chain, and spinal accessory nerve (XI). These
lesions are often multiple and can be associated with neurofi-
bromatosis type I, in which case there is a higher incidence
of malignancy. Removal of these tumors usually involves
sacrificing the nerve from which it arises.
6 | MISCELLANEOUS TUMORS
A wide variety of more than 40 different types of benign
(70%) and malignant (30%) neoplasms can occur in the PPS
and account for 10% of lesions.2 A comprehensive list is
beyond the scope of this review but may be grouped into
soft tissue tumors, bone tumors, and inflammatory tumors.
Some possible masses include ICA aneurysms, branchial
cleft cysts, hemangiomas, lymphogenic malformations, arte-
riovenous malformations, meningiomas, teratomas, and lipo-
mas. Lymphomas are the commonest malignant lesions in
this group.
7 | CLINICAL EVALUATION
The signs and symptoms of PPS neoplasms can be subtle
and clinical evaluation of this space is difficult. A signifi-
cantly number of patients have asymptomatic growth for a
long period, and the tumor is detected during a routine
checkup or while scanning for other reasons.10 In most
cases, tumors are slow-growing lesions and symptoms do
not appear until the tumor reaches certain dimensions or
affects nerve structures, so their diagnosis is usually late.
Whereas Sun et al10 reported that 44% of the patients have
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no symptoms and 23% of the patients have no clinical signs
and that it is a potential challenge for surgeons not to induce
or worsen symptoms by the treatment of these tumors.
The most frequent clinical signs and symptoms are a pal-
pable cervical mass or an intraoral swelling, which are pre-
sent in more than half of the cases. Symptoms related to
mass effect of the tumor or neural invasion are also com-
mon.2,10 These include pain, dysphagia, dysphonia, dyspnea,
dysarthria, otalgia, snoring, or foreign body sensation. In
paragangliomas, symptoms of catecholamine excess like
hypertension and flushing can be present.10
All patients should undergo a comprehensive medical
history and head and neck examination, including nasophar-
yngoscopy, audiological and cranial nerve assessment, and
airway, speech, and swallowing evaluation. If the lesion is
large enough to be palpated, bimanual palpation is impor-
tant. Tumors must reach a size of 2.5-3 cm before becoming
palpable as a mass because of the deep location in the neck,
so they can reach a large size prior to presentation.4,22 PPS
lesions usually enlarge medially and inferiorly; medial
enlargement results in an asymmetric intraoral smooth and
submucosal swelling and downward growth manifests as a
mass in the neck at the angle of the mandible.23,24 Parotid
lesions typically distort the tonsil, while neurogenic lesions
distort the posterior pharynx and posterior tonsillar pillar.25
The presence of a parotid mass in conjunction with an
intraoral mass suggests a “dumbbell”-shaped deep lobe
parotid tumor.
Tumors expanding into the retrostyloid compartment
may compress cranial nerves IX through to XII and the cer-
vical sympathetic chain. The presence of vagal dysfunction
with vocal cord palsy and Horner's syndrome are the most
frequent nerve disturbances and are a reason for further
investigation. Cranial nerve deficits and medial enlargement
of masses may lead to symptoms of dysphagia, dysphonia
and dyspnea. Superior enlargement of masses can compress
the opening of the Eustachian tube (24) leading to unilateral
middle ear effusion and its resulting sequelae.25
In selective cases, fine needle aspiration cytology
(FNAC) of the lesion can be useful if a malignant tumor is
suspected, but its widespread use is controversial; this
should only be performed after imaging to rule out a vascu-
lar lesion. Results with FNAC are variably reported by dif-
ferent authors.26,27 Combining FNAC with ultrasound or CT
seems to offer more accurate results.2 Peroral or transcervi-
cal FNAC can reach an accuracy of up to 90%-95%, with a
higher accuracy in malignant tumors as compared to benign
ones.11,28 The rate of nondiagnostic FNAC is moderately
high (25%-60%) as a result of excessive bleeding, lack of
cellular material, and other technical problems related to
adequately targeting the lesion in close vicinity of major
neck vessels.14,29,30 Transoral incisional biopsy is to be con-
demned, be it of lesions of salivary gland origin (because it
complicates removal and is associated with tumor spillage)
or of paragangliomas (in which the diagnosis with imaging
is accurate enough for treatment planning).29,30
8 | IMAGING
Cross-sectional imaging is essential when a parapharyngeal
tumor is suspected.7,31 CT, MRI, and magnetic resonance
(MR) angiography are complementary in the evaluation of
the tumor-host interface, neurovascular structures, glandular
and soft tissue, and the relationship to the skull base. Both
CT and MRI are essential for all types of PPS tumors, partic-
ularly those that are extensive, potentially malignant, or in
the setting of recurrence. Angiography should be considered
for all enhancing lesions, when preoperative embolization is
envisaged. If catecholamine levels are positive, a metaiodo-
benzylguanidine scan should be performed to investigate
catecholamine uptake and storage. In cases in which
paraganglioma is suspected, somatostatin analog imaging
such as32 Ga-DOTATATE PET/CT is a functional imaging
modality for evaluating these tumors.
Three main issues should be taken into account when
evaluating imaging studies: (1) the relationship of the airway
with the tumor and its possible involvement during treatment
should be assessed in the coronal images; (2) the axial slices
allow us to determine its exact location, observe the contrast
uptake, and determine its relationship with the parotid and
ICA; and (3) in the coronal and sagittal slices, we can
observe the relationship of the tumor with the base of the
skull. Moreover, there are some characteristics that suggest
malignancy such as the invasion of adjacent muscle and fat,
bone destruction, irregular tumor margins, obliterated fascial
planes, and lymphadenopathy. With combination of infor-
mation on precise tumor location and imaging characteris-
tics, multidetector-row CT and MR findings could be used
for prediction of tumor type. Recently, in group of 84 tumors,
an imaging-based histopathological diagnosis was found to
be in agreement with the final histological diagnosis in 92%
of the tumors: in all paragangliomas, in 77% pleomorphic
adenomas, and in 90% of schwannomas.33
As a whole, prestyloid tumors displace the ICA posteri-
orly in CT or MRI and retrostyloid tumors displace the ICA
anteromedially (Figures 1 and 2).24 This facilitates differen-
tiation between salivary gland tumors and neurogenic
tumors. Moreover, it is possible to differentiate whether a
schwannomas originates from the vagus nerve or the sympa-
thetic chain according to the Fukurawa et al34 criteria. In
schwannomas of the vagus nerve, the schwannoma grew
between the common carotid artery and the IJV or between
the ICA and the IJV, resulting in an increase in the distance
between the artery and vein (separation). In schwannomas of
the cervical sympathetic chain, no separation was observed
between the IJV and the common carotid artery or ICA.
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9 | CT SCAN
Information obtained from this study includes the location of
a tumor in either the prestyloid or retrostyloid compartments,
the presence or absence of a fat plane between the deep lobe
of the parotid for a prestyloid mass, and degree of contrast
enhancement. CT can demonstrate bony involvement and
calcification within lesions. Bone invasion by malignant
tumors can be seen, whereas bone erosion may occur by
benign and (slowly growing) malignant tumors.
Schwannomas enhance because of the extravascular
accumulation of contrast while a paraganglioma is a
hypervascular mass.
If a retrostyloid mass is found or if malignancy is sus-
pected, an MRI should be obtained.
10 | MRI
MRI is the first choice in the evaluation of parapharyngeal
masses. It is able to better outline the position of the great
vessels relative to the lesion, to delineate soft tissue and to
demonstrate intracranial extension. The relationship between
the mass and the ICA can be more clearly seen with MRI
than with CT scan.
There are characteristic appearances of different tumors
on MRI scan. Pleomorphic adenomas have low signal inten-
sity on T1 images and high on T2 images and displace the
ICA posteriorly. Schwannomas are isointense or hypointense
on T1 images, with intense enhancement with gadolinium,
and have higher signal intensity on T2 images like pleomor-
phic adenomas but displace the carotid anteromedially and
may show cystic degeneration. Paragangliomas have a char-
acteristic “salt and pepper” appearance on T2-weighted
images because of flow voids. Flow voids are also typically
observed in arteriovenous malformations.
11 | ANGIOGRAPHY
Selective preoperative angiography is usually recommended
for large vagal and jugular paragangliomas, carotid body
tumors, and other enhancing, vascular lesions.22 This study
can demonstrate the relationship of the tumor to the great
vessels and distinguish between neurogenic and vascular
lesions. Angiography can be diagnostic of some lesions.
Carotid body tumors cause splaying at the bifurcation result-
ing in the “lyre” sign. For the majority of jugular and vagal
paragangliomas, preoperative embolization is recommended
because of the difficulty that can be encountered in obtaining
proximal and distal vascular control prior to tumor manipu-
lation. However, there are conflicting data on the benefit of
embolization in carotid body tumors and it may not be nec-
essary.35 Moreover, carotid artery balloon occlusion tests
FIGURE 1 Retrostyloid space tumors. A, Axial T1-enhanced MRI shows a sympathetic schwannoma (*); and B, proton density axial sequence MRI shows
a vagal schwannoma (§). Both tumors displace the ICA (arrow) and the IJV (arrowhead) laterally and demonstrate homogeneous enhancement during venous
phase. Separation between the ICA and IJV can be seen when the tumor originates in the vagus nerve. C, Axial T2 with fat saturation shows a vagal
paraganglioma (¶). Diffusely enhancing mass adjacent to the skull base and centered high in the retrostyloid space. It displaces the ICA anteromedially
(arrow) and IJV (arrowhead) [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Prestyloid space tumor. Axial T2 MRI shows a pleomorphic
adenoma of the deep parotid lobe (*) bulging to the prestyloid PPS. Note
posterolateral displacement of the ICA and IJV
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should be performed if ICA infiltration is suspected or if
there is the possibility of ICA sacrifice.6,29,30 In arteriove-
nous malformations, preoperative angiography with emboli-
zation is used to decrease blood loss during surgical
resection.
CT angiography or MR angiography can be used for vas-
cular mapping and to define the relationship of the tumor to
the vessels and can define the competence of the circle of
Willis anatomy and its potential for contralateral intracranial
carotid blood flow.
12 | MANAGEMENT
The most widely used treatment for these tumors is surgical
resection.36 Riffat et al2 report that 95% of the 1143 patients
included in their study were treated by surgical resection. As
most tumors are benign, complete surgical resection without
causing additional major functional and aesthetic sequelae to
the patient is the primary goal of surgery. Most prestyloid
lesions can usually be treated safely because potential post-
operative morbidity is low. Nevertheless, neurovascular
complications are more likely in the surgical treatment of
retrostyloid lesions, particularly in the case of vagal paragan-
glioma. Thus, in a systematic review on vagal paraganglio-
mas, the vagal nerve was functionally preserved in only
11 of 254 surgically treated patients (4.3%).37 As a conse-
quence, not all patients should be operated on and surgery
will not be indicated if the risks of surgery outweigh those
of nonsurgical treatment or a “wait and see” policy. Elderly
patients with asymptomatic benign tumors and patients with
slow-growing benign tumors or neurogenic lesions, which
are at high risk of cranial nerve damage if they are operated,
should be managed with caution, and surgery should be
avoided if it is expected to cause iatrogenic morbidity. A
gradual loss of nerve function is usually better tolerated than
sudden loss as a result of surgery, so observation or delayed
removal is recommended in patients with normal neural
function. Also, for some paragangliomas that are not func-
tioning, a primary nonsurgical approach is often
recommended.37
Patients with unresectable lesions, extended malignant
lesions, and with ICA involvement, who have failed the bal-
loon occlusion test, may not be suitable for surgery. More-
over, those patients with pre-existing contralateral deficits of
the vagal and hypoglossal nerves may not be suitable for
surgery because of the risk of bilateral deficits causing prob-
lems with swallowing and the airway. In these cases, radio-
therapy is usually the primary modality of treatment. The
same can be said of those vagal paraganglioma or vagal neu-
romas that experience appreciable growth during follow-up,
as tumor control, major complication rates, and the number
of cranial nerve palsies after treatment are significantly
lower in radiotherapy than in surgical series.37
Adjuvant radiotherapy should be used in patients with
malignancies, in those patients with potentially aggressive
neoplasms in which wide surgical margins cannot be
obtained, and in patients with incomplete resections. Despite
this, malignant tumors present high recurrence rates and
poor prognosis.
13 | SURGERY
Surgery of the PPS is a great challenge. Various approaches
to the PPS have been described.29,30 All approaches can be
used separately or in combination to obtain better exposure
and resection of tumors. The choice of surgical approach is
based on tumor size, location, histopathology, vascularity,
superior extent and relationship to critical neurovascular
structures, and the skull base, as well as host characteristics.
An appropriate approach should allow wide enough expo-
sure of the tumor for achieving complete resection and man-
age the eventual complications, with minimal aesthetic and
functional morbidity.38 It is mandatory to preserve the integ-
rity of the capsule (or pseudocapsule) to avoid tumor spill-
age. The surgeon's skills and experience are crucial for
choosing the optimal approach because each one has advan-
tages and limitations. Accordingly, more-experienced sur-
geons can perform more limited approaches to remove large
tumors. Prasad et al9 has proposed an algorithm for the
selection of appropriate surgical approaches in the manage-
ment of PPS tumors. Table 2 describes the main approaches
used and their indications.
In general, large tumors, highly vascularized lesions
especially in close proximity to the skull base or neurovascu-
lar bundle, as well as malignancies usually require wider
access. Tumors spanning the superior portion of the PPS can
be completely removed through a skull base approach. To
remove a large tumor in the middle and inferior portion of
the PPS, a transparotid approach is the most suitable.
Finally, a tumor in the inferior portion of the PPS is best
accessed through a transcervical approach.39 However, the
vast majority of benign tumors of the prestyloid space,
regardless of their superior extension, can be resected by a
transcervical, transparotid, or combined approach.
The most widely used surgical approach is the transcer-
vical approach (Figure 3).10,16,29,30,40,41 Riffat et al2 report
that in up to 48% of the 686 cases undergoing surgery, a
transcervical approach was used. This approach allows to a
satisfactory exposure of tumors and permits a good visuali-
zation of the cranial nerves and the control of the great ves-
sels around them and avoids jeopardizing the facial nerve.
This approach is used especially when the tumors (benign
and malignant) are located in the inferior portion of the PPS,
between the carotid sheath and pharyngeal constrictor mus-
cles and when they do not displace the parotid gland later-
ally. The main limitation of this approach is the poor
exposure of the medial and superior aspects of PPS and the
528 LÓPEZ ET AL.
limited working space, with insufficient exposure of tumors
approaching the base of the skull.42 For this reason, some
surgeons combine this approach with other approaches, spe-
cially the transoral approach. A transverse incision at the
level of the hyoid bone with either removal or displacement
medially of the submandibular gland is performed. An inci-
sion is made in the posterior fascia of the submandibular
gland and the digastric muscle and stylohyoid and hyoglos-
sus muscles can be released from the hyoid bone, which can
be resected partially. To increase the exposure, the styloid
process may be cut at its origin along with Ryolan's bundle
and the posterior belly of the digastric and the
stylomandibular ligament can be divided, obtaining a better
exposure of the upper portion of the PPS.4,43 Delicate dis-
section proceeds upward to reach the upper pole of the mass
and, finally, tumors may often be bluntly dissected. If neces-
sary, this approach can be extended with a mandibulotomy,
transparotid, or transmastoid approaches.
An isolated transparotid approach or combined with a
transcervical approach may be indicated if lesions are in
close proximity to the facial nerve, including deep lobe
parotid tumors extended to the PPS and minor salivary gland
tumors (Figure 4).5,41 This approach is also appropriated for
retrostyloid tumors located in the mid and upper portion of
FIGURE 3 A, Diffusion-weighted imaging MRI shows a sympathetic schwannoma (*) tumor displacing the great vessels (arrow) anteriorly. B, This tumor
was removed by a transcervical approach. Postoperative specimen with intact capsule (inset) [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Main surgical approachesa
Approach Indications Surgical suggestions
Transcervical Tumors (benign and malignant) located in the middle and
inferior portion of the PPS and benign tumors adjacent to
the skull base
-The posterior belly of the digastric Mzuscle may be resected
-The extra-temporal facial nerve may be identified if necessary
-The styloid process may be transected
Cervico-parotid Deep lobe parotid tumors and tumors involving the facial
nerve and tumors located in the upper portion of the PPS
-In addition to transcervical approach
-Parotidectomy with preservation of the facial nerve
Mandibular splitb Selected malignant, recurrent or large tumors involving
ICA and adjacent to the skull base
-The inferior alveolar nerve should be preserved
Transcervical-
transmastoid
approach
Tumors of the upper PPS with a limited posterior extension -In addition to transcervical approach
-The mastoid tip is removed
-The facial nerve is left in its canal
-An infralabyrinthine dissection can be performed to expose the
sigmoid sinus and the jugular bulb to control the most inferior part
of the tumor
Infratemporal
fossa approaches
types A, B, or D
Tumors involving the skull base or jugular foramen,
extending into the infratemporal fossa, or with significant
intracranial extension
-Type A: Tumors of the upper PPS with extension to the
vertical tract of the ICA
-Type B: Tumors of the upper PPS with an antero-medial
extension with respect to ICA
-Type D: Tumors of the upper PPS with an anterolateral
extension with respect to ICA
-Type A: Anterior transposition of the facial nerve is performed to
provide optimal exposure of the jugular foramen and to allow
control over the distal parapharyngeal ICA up to the vertical petrous
portion and concurrent removal of small intradural tumor
extensions
-Type B: The facial nerve is identified and left in situ without any
manipulation; this approach provided access to the vertical and
horizontal portions of the petrous ICA, petrous apex, and mid to
lower clivus.
-Type D: Preauricular incision with a plane of dissection anterior to
the horizontal petrous ICA and the eustachian tube giving access to
the nasopharynx, the pterygopalatine Fossa, and the anterosuperior
PPS
Transoral Selected small benign tumors of the prestyloid space -Endoscope-assisted resection
-Transoral robotic resection
a Different approaches can be combined according to tumor characteristics and surgical skills.
b Currently, transmandibular approaches have been minimized.
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the PPS. The cervical approach is combined with a parotid
approach by using a parotidectomy incision in front of the
ear. This allows identification of the facial nerve trunk and
lower division of the facial nerve, as well as exposing the
ICA, jugular vein, and cranial nerves. An essential surgical
step is prognathic dislocation of the mandible, following sty-
lomandibular ligament and styloid muscle division, which
would be favored by a nasal intubation. This can widen the
exposure by more than 50%.44
Intraoperative monitoring facilitates the identification of
the facial nerve and reduces the risk of unintended lesions,
even when limiting surgical access to a purely transcervical
route for aesthetic reasons.36 Parotid tissue resection is not
always necessary, leaving the superficial parotid in place is
aesthetically beneficial.
Currently, performing a mandibulotomy has few indica-
tions and in expert hands can be avoided in most
cases.29,30,45 It is required in <10% of patients, including
those with malignant, recurrent, or large tumors requiring a
wide exposure, especially when there are concerns about the
potential involvement of great cervical vessels.2,3,15,46 This
procedure requires a delay in oral nutrition and may necessi-
tate a tracheostomy as a result of the risk of postsurgical air-
way obstruction. Moreover, it carries the potential for a
mandibular malunion, loss of dentition, and temporomandib-
ular joint dysfunction. Mandibulotomy may be indicated for
selected patients. Tumors located in the upper portion of the
PPS and lesions that require distal control of the ICA or
extensive exposure of the skull base are also candidates.
Mandibulotomy of the body (median or paramedian), ramus,
or the angle should preserve the inferior alveolar nerve as
well as the hypoglossal and the lingual nerves although at
risk in this approach. Some authors perform a non-lip-
splitting mandibulotomy omitting the procedure of lower
lip-splitting incision to improve the aesthetic results and to
decrease the functional morbidities of the lower lip.47–50
An infratemporal fossa approach type A, B, or D may be
used for tumors involving the skull base or jugular foramen,
extending into the infratemporal fossa or with significant
intracranial extension (Figure 5).9,51 Tumors with invasion
of the PPS and the infratemporal fossa with extension to the
floor of the middle cranial fossa can be removed by means
of the preauricular subtemporal approach with low morbid-
ity.52 Adequate ICA management is essential when planning
surgical treatment for PPS lesions, especially in the presence
of a limited working space and if there is a close relationship
between the tumor and the ICA. If the tumor surrounds the
ICA for more than half of its circumference, if there is
FIGURE 4 A, Axial T2 MRI shows the posterior displacement of the vessels (arrow) by a large pleomorphic adenoma (*). B, This tumor (*) was removed
through a transcervical-transparotid approach, with preservation of the facial nerve (VII) [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 5 A, Axial CT shows a malignant fibrous histiocytoma (*) removed by an infratemporal fossa approach (B). C, Large, deep space left after
resection of a tumor with preservation of the facial nerve (VII) [Color figure can be viewed at wileyonlinelibrary.com]
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evidence of stenosis, in cases of previous treatment (radio-
therapy and surgery), if a single ipsilateral ICA is identified,
and in glomus tumors, patients should be considered at risk.
Subadventitial dissection or stenting of ICA gives a chance
for complete tumor removal with arterial preservation,9,53
but in benign tumors, the disadvantages outweigh the advan-
tages. For all tumors in which a risk for ICA damage and the
need for shunting exists, surgeons' comfort can be improved
by the use of near-infrared cerebral oximetry to monitor
brain oxygenation.54–56 Carotid artery sacrifice and recon-
struction should be avoided, although acceptable complica-
tion rates are reported in highly selected head and neck
squamous cell carcinoma patients.57
Some years ago, transoral approaches were contraindi-
cated but nowadays are advocated by some authors for
selected small benign lesions of the prestyloid space present-
ing as an oropharyngeal and avascular mass and those not
palpable in the neck or parotid.4,16,28,58 Problems with this
approach are the limited exposure and the lack of control of
the neck great vessels and the cranial nerves and, hence, pos-
sibility of neurovascular injury. An increased risk of tumor
rupture or incomplete removal and contamination of the sur-
gical field from saliva, with an increased risk of infections
and wound dehiscence are other criticisms. Nevertheless
some reports confirm the feasibility of the transoral route
with few cases of tumor rupture or recurrence provided that
a careful evaluation of indications and potential drawbacks
is made before considering this approach, especially in sali-
vary tumors.59–61
Minimally invasive approaches have been advocated to
minimize surgical morbidity while claiming complete PPS
tumor resection. In general, the use of endoscopic
approaches has not been standardized and should be used
only in selected cases and performed by highly skilled
surgeons.62–65 Wang et al66 have reported that although PPS
tumors may be completely removed by both external and
transoral endoscopic approaches, the latter has the advan-
tages of reduced blood loss and postoperative pain level and
preservation of facial cosmetic. Similar results have been
reported by Fan et al.67 Endoscope-assisted transoral re-
section provides a wider view, reducing the risks of neuro-
vascular injury or capsule rupture and allowing resection of
large tumors64,65; those tumors surrounded major vascular
structures or with large lateral extension are not suitable.
Endoscopy may also be used to overcome some of the limi-
tations of external conventional approaches.12 It may be use-
ful to visualize and dissect structures surrounding the tumor
especially in the upper PPS, when reaching the skull base.68
Furthermore, endoscopy provides an excellent visualization
of areas beyond the line of direct sight and enables confirma-
tion of adequate hemostasis and the absence of residual
tumor before closure. A variant of this technique is the mini-
mally invasive video-assisted transcervical approach, which
has shown to be safe and feasible for selected benign and
malignant PPS tumors.69 Nevertheless, the use of endo-
scopic approaches has not been standardized and should be
used only in selected cases and performed by highly skilled
surgeons experienced in this approach.
Transnasal endoscopic access by means of a transptery-
goid approach allows access to the upper part of the
PPS.32,70 Wasano et al71 have described the modified endo-
scopic transnasal-transmaxillary-transpterygoid approach, in
which the surgical corridor to the PPS consists of the maxil-
lary sinus, submucous tunnel under the lateral nasal wall,
and the space created by removing the pterygoid process.
This deep region has traditionally been approached through
open lateral or anterior approaches, which are associated
with several significant complications.72–74 Endoscopic
approaches may provide the surgeon with a minimally inva-
sive and safe approach to radically resect selected tumors
involving the upper PPS and thus reduce the needs for lateral
approach or mandibulotomy.75 Further studies are needed to
validate the reproducibility and efficacy of this technique. In
addition, the consequences of creating a large sinonasal cav-
ity are not negligible.
The use of transoral robotic surgery (TORS) has recently
been attempted for the treatment of these tumors.76–78 Visual
magnification and the precision of robotic instruments help
the delicate dissection and avoidance of tumor fragmenta-
tion.14 Nevertheless, some authors have reported that capsule
disruption may occur but with no obvious impact on the
recurrence rate or the need for a transcervical conver-
sion.14,76,77 TORS candidates are patients with adequate
exposure of the oropharynx and whose preoperative assess-
ment revealed a well-circumscribed neoplasm with lateral
displacement of the ICA and clear cleavage plane from neu-
rovascular bundle.14,79 TORS extends the advantages of the
transoral conventional approach, allowing for the manage-
ment of larger tumors. TORS may be used in both pre- and
retrostyloid tumors and either benign or malignant cases.
Boyce et al77 have reported the successful removal of
17 PPS tumors that ranged from 2 to 80 cm3, only two of
them requiring a complementary cervical incision to assist
with tumor removal. The far lateral and superior areas of the
PPS, which required transcervical assistance, are inaccessi-
ble by this technique.77 Some authors have combined the
use of endoscopy with TORS80; transcervical endoscopy is
used for circumferential separation of the tumor from the
neurovascular structures of the skull base, and then, after the
tumor is separated, it is removed en bloc, via TORS. This
approach could be utilized for the removal of large benign
tumors, or small tumors located high at the skull base.
Approaching PPS tumors by this approach should be
reserved to very experienced transoral robotic surgeons.
Microdebrider-assisted volume reduction may be an ele-
gant adjunct to facilitate resection in certain situations.81,82
Certain PPS schwannomas can be addressed by using this
technique via a purely transcervical or transoral approaches;
LÓPEZ ET AL. 531
for vagal schwannomas, neuromonitoring can be combined
to maximize nerve function preservation. Progressive
debulking of the tumor allows its upper portion to be visual-
ized and a better delineation of its relationships with sur-
rounding structures, facilitating a safe resection through a
limited cervical incision. The main disadvantage of this tech-
nique in PPS neurogenic tumors is its inability to preserve
nerve function as the entire nerve is resected together with
the tumor capsule. Nevertheless, intracapsular enucleation of
schwannomas, avoiding damage to the surrounding nerve
fibers, may be an option to achieve a functional
preservation,83–85 although late recurrences have been
described.86 Unlike neurogenic tumors, that have a thick
capsule and a low risk of recurrence, in salivary tumors, cap-
sule rupture may be associated with tumor spillage and ele-
vated risk of recurrence. Therefore, caution should be taken
with this technique and it does not seem suitable for salivary
gland tumors. Both techniques may be combined with endo-
scopic or robot-assisted approaches.
14 | NONSURGICAL MANAGEMENT
In some cases of patients who are poor surgical candidates,
who fail balloon occlusion, are elderly, have unresectable
lesions, or have benign slow-growing tumors that would
require sacrifice of multiple cranial nerves, surgery may not
be the only option or the treatment of choice. Other options
include observation and radiation.
Of important note, especially for paraganglioma, an ini-
tial “wait and scan” policy is recommendable in many
patients. This policy was promoted in the Netherlands
decades ago, following the observation in 108 patients that
no growth occurred in more than half of the patients. Com-
paring surgical patients to observed patients, survival was
equal but complications went two times greater in the surgi-
cal arm.87 This has been corroborated in other settings. Lan-
german et al3 documented that in 43 patients: 20% of tumors
showed regression, 42% remained stable in size, while only
38% grew at mean 2 mm/y.88 This “wait and scan” policy
can also be applied on radiologically benign neurogenic ret-
rostyloid lesions such as schwannomas.
Given the rarity of the condition, there are no random-
ized controlled trials yet to compare surgery with radiother-
apy for PPS lesions. However, in some tumors, the
usefulness of radiotherapy has been demonstrated. The first
on the list are large and clinically apparent paragangliomas
and schwannomas when incomplete resection and, in partic-
ular, impairment of cranial nerves are expected if treated sur-
gically. In such cases, radiotherapy is a valid or even
preferred option.37,89 To abolish growth potential of these
lesions, rather low radiation doses are sufficient. Indeed, no
dose higher than 45 Gy showed any advantage in term of
local control. In such scenario, radiotherapy usually induces
cessation of further growth of the lesion or reduction in its
size, rather than complete eradication of tumor, which is the
goal of surgical intervention. Furthermore, side effects are
insignificant when doses below 50 Gy and modern radiation
techniques (intensity modulated or stereotactic) are used.
Although radiation is not curable for paragangliomas, that
means that the tumor persists, there is no growth, or progres-
sive neurological involvement in up to 96%-100% of
cases.37,90,91
Similar considerations apply to pleomorphic adenoma,
when symptomatic and inoperable or in cases presented with
multinodular and/or multiple recurrent tumors.92 Although
the cure of large tumors with radiotherapy is less likely, radi-
ation proved to be effective in postoperative setting, which
was demonstrated in several retrospective series. However,
selection of patients for radiotherapy after incomplete sur-
gery in attempt to prevent further recurrences of a benign
tumor must be weighed against patient's age, possibility for
additional surgery, and the risk of malignant transformation.
The latter increases with time and with the number of recur-
rences. Fractionated proton beam radiotherapy to 45-50 Gy
has been recommended, although the use of neutron radio-
therapy to treat recurrent pleomorphic adenoma has also
been reported.93 Although observation is a fair option for
elderly or medically unfit patients or those with small
lesions.
15 | COMPLICATIONS AND OUTCOMES
Complications related to surgery are not very common if
performed by expert surgeons. Nevertheless, potential com-
plications should be explained to patients prior to surgery.
Malignant tumors and neurogenic lesions have the great risk
of injury.
Overall, the most common complications are cranial
nerve injuries.13 The vagal nerve is the most commonly
affected, mainly in retrostyloid tumors. Its injury results in
vocal cord palsy but mainly a severe pharyngeal palsy, caus-
ing potentially very severe alterations in phonation and swal-
lowing. These patients, if a spontaneous compensation does
not occur, may require treatment with speech therapy and
rehabilitation of swallowing. Not infrequently, a medializa-
tion thyroplasty or intracordal injection may be necessary.
This may be done during tumor removal surgery if the nerve
is intentionally sacrificed. Performing the thyroplasty con-
comitant to the vagus nerve resection offers better results
(voice and swallowing) compared when it is done in a
delayed way.94 The facial nerve may also be injured in pre-
styloid tumors and repair techniques may be required.
The first bite syndrome95 is the major complaint after
otherwise uncomplicated surgery of the PPS. It is described
as an acute and intense pain in the parotid region caused
with the first bite of each meal. It is related to damage to
sympathetic innervation of the parotid gland. Botulinum
toxin A injection into the affected parotid gland produces a
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decrease in the severity of symptoms. It is a safe and viable
noninvasive treatment for this difficult to treat condition and
may lead to permanent resolution of symptoms in some
patients. Other complications include, Claude Bernard Hor-
ner syndrome14 and the dysfunction of temporomandibular
junction. Hematoma, infections (phlegmone and abscess for-
mation), and trismus may also be observed. Hemorrhage
resulting from vascular injury is hazardous but rare.
16 | CONCLUSION
Tumors of the PPS arise in an anatomically complex region
of the body. Furthermore, the low incidence of such tumors
and their histological diversity have hampered diagnosis and
management and prevented the accumulation of clinical
experience at individual institutions. Nevertheless, the clini-
cal management of these tumors has improved as a result of
advances in imaging and surgical techniques. The clinical
presentation of these tumors can be subtle. Therefore, radio-
logical imaging provides critical information for diagnosis
and surgical planning. The goal of treatment is complete
tumor resection while limiting the aesthetic and functional
sequelae. Surgery of PPS tumors has always been challeng-
ing because of the deep location, which limits visualization
and manipulation, and the presence of important neurovas-
cular structures that require adequate exposure and careful
management to avoid complications. The transcervical
approach is the most widely used, although the use of endo-
scopes and the refinement of surgical techniques made more
limited approaches possible. Further long-term evaluation is
needed to define patient selection and the role of endoscopy
and TORS for PPS neoplasms.
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